Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.

BMC Cancer · 2021 · PMC8549287 · PMID 34706686

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although comparison of OS across the entire follow-up period did not reach statistical significance, we did observe higher 1-year and 2-year OS rates in the pertuzumab-pretreated cohort.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.